ABOUT THIS BOOK
· The book will have most upto-date and complete information on omics
of breast cancer ?
· Chapters focused on early diagnosis, prognosis, and targeted therapy
· Covers breast cancer miRNA, lipidomics, pharmacogenomics, epigenomics, proteomics, nutrigenomics and stem cell
Breast cancer is the most common cancer in females that accounts for highest cancer specific deaths worldwide. In last few decades research has proven that breast cancer can be treated if diagnosed at very early stage and proper therapeutic strategy is adopted. Omics-based recent approaches have unveiled the molecular mechanism behind the breast tumorgenesis and aid in identification of next-generation molecular markers for early diagnosis, prognosis, and even the effective targeted therapy. Significant development has taken place in the field of omics in breast cancer in the last decade. The most promising omics approaches and their outcomes in breast cancer have been presented in this book for the first time. The book covers omics technologies and budding fields such as breast cancer miRNA, lipidomics, epigenomics, proteomics, nutrigenomics, stem cell, pharmacogenomics and personalized medicine, and many more along with conventional topics such as breast cancer management etc. It is a research-based reference book and will be a useful resource for clinician-scientists, researchers, geneticists, health care industries involved in various aspects of breast cancer. Apart from these, the book will be useful to students in biomedicine, pathology, and pharmacy.
Content Level » Professional/practitioner
Keywords » Breast cancer research - Cancer - Cancer biomarkers - Cancer proteomics -Gynecological cancer - Omics in breast cancer
Related subjects » Cancer Research - Gynecology - Human Genetics - Oncology & Hematology -Pathology
TABLE OF CONTENTS
-Gynecologic considerations in women with breast cancer .-Omics technology applied in breast cancer research .-Breast cancer genomics .-Pharmacogenomics –pharmacoepigenomics: clinical implications for personalized medicine in breast cancer.-Dna methylation and breast cancer: role of nutrition in methylation of breast cancer.-Nutrigenomics of breast cancer .-Breast cancer proteomics .-Breast cancer mirna.-Lipidomics in breast cancer .-Imaging technologies and applications in early diagnosis and prognosis for breast cancer.-Early detection biomarkers in breast carcinogenesis.-Molecular diagnosis of metastasizing breast cancer based upon liquid biopsy.-The role of circulating tumor cells to monitor the antineoplastic treatment of metastastic breast cancer .-Circulating breast cancer stem cells: potential biomarkers for breast cancer diagnosis and prognosis evaluation .-Breast cancer therapy- classical therapy, drug targets and targeted therapy .-Challenges in interpreting the role of transforming growth factor ß (tgf-ß) and forkhead box p3 (foxp3) in breast cancer microenvironment
AUTHORS & EDITORS
Dr Debmalya Barh is the founder of Institute of Integrative Omics and Applied Biotechnology (IIOAB) at Nonakuri, Tamluk, West Bengal, India. His core competencies include bioinformatics, genome, genomics and proteomics, cell signaling, integrative omics based marker and target discovery, cancer pharmacogenomics, personalized medicine, cardiovascular and infectious diseases. He has been a consultant for three top healthcare and diagnostic companies in USA. He is the reviewer/editorial board member of many journals like CMAJ, Molecular Medicine, Bioinformatics, BMC Genomics, BMC Systems Biology, Journal of Medical Informatics, Current Oncology, Gene Therapy, J. Cardiovascular Dis Res, J Integrated Omics, AIOAB. He has several scientific publications including genome sequences, journal articles, book chapters and reference books.